Viatris Inc.
VTRS
Positions held
Your positionsVTRS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Viatris Inc. operates in a competitive healthcare sector with a strong focus on specialty and generic drugs, positioning itself well to meet diverse patient needs.
- Revenue increased by 7% compared to the prior quarter, reaching $3.8 billion.
- Gross margin improved to 38.8%, up from 32.9% in the previous quarter.
- Despite its competitive positioning, Viatris faces challenges with a negative profit margin and high debt-to-equity ratio, which may impact long-term sustainability.
- The company reported a net income loss of $118.8 million in the latest quarter.
- Operating margin remains low at 2%, indicating ongoing operational challenges.
Fundamentals
| Market cap | $20.03B | Enterprise value | $32.14B | Trailing P/E | — | Forward P/E | 6.52 |
| PEG | 3.19 | Price / book | 1.39 | Beta | 0.86 | Dividend yield | 2.75% |
| Revenue growth | 4.9% | Earnings growth | — | Gross margin | 40.3% | Operating margin | 12.6% |
| Profit margin | -2.8% | ROE | -2.8% | ROA | 2.7% | Debt / equity | 0.96 |
| Current ratio | 1.59 | Free cash flow | $2.68B | Analyst recommendation | buy | Mean target | $19.70 |
| 52w high | $18.43 | 52w low | $9.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.5B | $3.7B | $3.8B | $3.6B |
| Op margin | 2.0% | -0.6% | -4.3% | 6.2% | 5.2% |
| Net income | -$119M | $176M | -$340M | -$128M | -$4.6M |
| Gross margin | 38.8% | 32.9% | 31.0% | 36.5% | 37.2% |
| Gross profit | $1.5B | $1.2B | $1.1B | $1.4B | $1.3B |
| Operating income | $73.7M | -$20.2M | -$158M | $235M | $185M |
- Revenue +7% vs prior quarter ($3.8B vs $3.5B).
- Gross margin 38.8% (was 32.9% prior quarter).
- Operating margin expanded to 2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $14.3B | $14.7B | $15.4B | $16.3B |
| Op margin | 1.8% | 4.8% | 10.1% | 10.2% |
| Net income | -$3.5B | -$634M | $54.7M | $2.1B |
| Gross margin | 35.1% | 38.2% | 41.7% | 40.0% |
| Gross profit | $5.0B | $5.6B | $6.4B | $6.5B |
| Operating income | $254M | $710M | $1.6B | $1.7B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
2026-10-09 · Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
2026-10-09 · Oppenheimer Downgrades Pacira Biosciences to Perform From Outperform on Heels of Announced Sale to Viatris
2026-10-09 · Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
2026-10-08 · Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
2026-10-08 · Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
2026-10-08 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-10-08 · Viatris to acquire Pacira BioSciences for $1.65 billion
2026-10-08 · Top Midday Gainers
2026-10-08 · Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?
2026-10-08 · HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
2026-10-08 · Sector Update: Healthcare Stocks Decline in Afternoon Trading
Price (daily)
Full chart · RSI · MACD · patterns